Nykode Therapeutics (OB:NYKD) - Cotización, noticias y análisis

Resumen de acción NYKD

Nykode Therapeutics AS, empresa biofarmacéutica en fase clínica, descubre y desarrolla inmunoterapias novedosas.

NYKD fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 30.98%

Análisis de riesgos

Se prevé que los beneficios disminuyan un promedio de 23.5% al año durante los próximos 3 años

Los accionistas han sido diluidos en el último año

Competidores de Nykode Therapeutics AS

ArcticZymes Technologies

OB:AZT

kr1.3b

Hofseth BioCare

OB:HBC

kr806.0m

Norda

OTCNO:NORD

kr203.8m

Arctic Bioscience

OB:ABS

kr266.4m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Nykode Therapeutics
Historical stock prices
Current Share Price	kr13.39
52 Week High	kr30.86
52 Week Low	kr12.38
Beta	1.41
1 Month Change	-5.04%
3 Month Change	-24.26%
1 Year Change	-48.93%
3 Year Change	-82.79%
5 Year Change	n/a
Change since IPO	-32.37%

Noticias y actualizaciones recientes

Recent updates

Earnings Update: Nykode Therapeutics AS (OB:NYKD) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Mar 02

Risks To Shareholder Returns Are Elevated At These Prices For Nykode Therapeutics AS (OB:NYKD)

Jan 22

We Think Nykode Therapeutics (OB:NYKD) Can Easily Afford To Drive Business Growth

Aug 20

Nykode Therapeutics (OB:NYKD) Is In A Strong Position To Grow Its Business

Apr 06

Could The Vaccibody AS (OB:VACC) Ownership Structure Tell Us Something Useful?

Jan 25

Rentabilidad de los accionistas

	NYKD	NO Biotechs	Mercado NO
7D	3.2%	1.0%	-0.5%
1Y	-48.9%	-65.9%	6.6%

Rentabilidad vs. Industria: NYKD superó al sector Norwegian Biotechs , que obtuvo un rendimiento del -67.2% el año pasado.

Rentabilidad vs. Mercado: NYKD obtuvo unos resultados inferiores a los del mercado Norwegian, que fue del 4.6% el año pasado.

Volatilidad de los precios

Is NYKD's price volatile compared to industry and market?
NYKD volatility
NYKD Average Weekly Movement	7.2%
Biotechs Industry Average Movement	9.2%
Market Average Movement	5.1%
10% most volatile stocks in NO Market	10.1%
10% least volatile stocks in NO Market	3.0%

Precio estable de las acciones: El precio de las acciones de NYKD ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de NYKD (7%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2006	172	Michael Engsig	nykode.com

Nykode Therapeutics AS, una empresa biofarmacéutica en fase clínica, descubre y desarrolla inmunoterapias novedosas. La empresa desarrolla vacunas para el tratamiento del cáncer y las enfermedades infecciosas. Sus principales productos candidatos son VB10

Resumen de fundamentos de Nykode Therapeutics AS

¿Cómo se comparan los beneficios e ingresos de Nykode Therapeutics con su capitalización de mercado?
Estadísticas fundamentales de NYKD
Capitalización bursátil	kr4.37b
Beneficios(TTM)	-kr384.08m
Ingresos (TTM)	kr145.56m

30.0x

Ratio precio-ventas (PS)

-11.4x

Ratio precio-beneficio (PE)

¿Está NYKD sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de NYKD
Ingresos	US$13.32m
Coste de los ingresos	US$0
Beneficio bruto	US$13.32m
Otros gastos	US$48.48m
Beneficios	-US$35.15m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

May 14, 2024

Beneficios por acción (BPA)	-0.11
Margen bruto	100.00%
Margen de beneficio neto	-263.86%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado NYKD a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción NYKD

Recompensas

Análisis de riesgos

Competidores de Nykode Therapeutics AS

OB:AZT

kr1.3b

OB:HBC

kr806.0m

OTCNO:NORD

kr203.8m

OB:ABS

kr266.4m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Nykode Therapeutics ASA Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer

Director recently bought kr310k worth of stock

Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer

Nykode Therapeutics ASA Announces Advances in the Inverse Vaccine Platform with the Potential to Treat Autoimmune Diseases

Price target decreased by 36% to kr43.00

Recent updates

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Nykode Therapeutics ASA Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer

Director recently bought kr310k worth of stock

Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer

Nykode Therapeutics ASA Announces Advances in the Inverse Vaccine Platform with the Potential to Treat Autoimmune Diseases

Price target decreased by 36% to kr43.00

Consensus EPS estimates upgraded to US$0.18 loss

Chief Executive Officer recently bought kr100k worth of stock

Earnings Update: Nykode Therapeutics AS (OB:NYKD) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Risks To Shareholder Returns Are Elevated At These Prices For Nykode Therapeutics AS (OB:NYKD)

Nykode Therapeutics AS to Report Q4, 2024 Results on Feb 26, 2025

Nykode Therapeutics Announces Expansion of Oncology Pipeline Aiming to Reduce the Burden of Colorectal Cancer

Third quarter 2023 earnings released: US$0.03 loss per share (vs US$0.05 loss in 3Q 2022)

New minor risk - Shareholder dilution

Nykode Therapeutics ASA Initiates Phase 1/2a Trial of VB10.16 in First Line HPV16-Positive Head and Neck Cancer

Nykode Therapeutics ASA Announces Advances in Clinical Pipeline and Research

Nykode Therapeutics ASA Announces FDA Approval of IND for VB-C-04, a Trial of VB-C-04 in HPV16-Positive Cervical Cancer

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

We Think Nykode Therapeutics (OB:NYKD) Can Easily Afford To Drive Business Growth

Nykode Therapeutics Announces Expansion of Clinical Collaboration with Roche to Evaluate VB10.16 in Combination with anti-PD-L1 in the Next Trial in Advanced Cervical Cancer

Nykode Therapeutics AS Announces Management Changes

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Nykode Therapeutics (OB:NYKD) Is In A Strong Position To Grow Its Business

Full year 2022 earnings released: US$0.15 loss per share (vs US$0.033 loss in FY 2021)

Director exercised options and sold kr7.4m worth of stock

Nykode Therapeutics AS to Report Q3, 2023 Results on Nov 15, 2023

Nykode Expands Clinical Development Plan for Its Lead Cancer Vaccine Vb10.16 in Hpv16-Positive Cancers

Third quarter 2022 earnings released: US$0.05 loss per share (vs US$0.03 loss in 3Q 2021)

No independent directors

Nykode Therapeutics Presents Additional Efficacy Analysis in Phase 2 Study of VB10.16 in Combination with Atezolizumab in Advanced Cervical Cancer

Nykode Therapeutics ASA Announces Presentation of Positive Immunogenicity Results from Phase 1/2A Study of VB10.NEO

Nykode Therapeutics ASA Announces Positive Results from the Phase 1/2 Open Label, Dose Escalation Trial of its T Cell Focused SARS-CoV-2 Vaccine Candidate

Second quarter 2022 earnings released: US$0.03 loss per share (vs US$0.02 loss in 2Q 2021)

Nykode Therapeutics Announces Positive Interim Results in HPV+ Cervical Cancer Phase 2 Trial

Nykode Therapeutics AS Appoints Klaus Edvardsen as Chief Development Officer, Effective from July 1, 2022

Chairman of the Board recently bought kr321k worth of stock

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Nykode Therapeutics AS Appoints Elaine Sullivan and Anne Whitaker to the Board of Directors

Nykode Therapeutics AS Announces Positive Interim Results from Its Phase 2 Trial with VB10.16 in Combination with Immune Checkpoint Inhibitor Atezolizumab in Advanced Cervical Cancer

No independent directors

Nykode Therapeutics as Announces Presentation of Preclinical Data from Its Second Generation Vaccibody Vaccine Technology At 2022 American Association for Cancer Research (AACR) Annual Meeting

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Nykode Therapeutics Announces Completion of Patient Enrollment in Its Phase 2 Trial of Vb10.16 in Combination with Atezolizumab for the Treatment of Advanced Cervical Cancer

Investor sentiment deteriorated over the past week

Nykode Therapeutics AS Announces First Subject Dosed with Its T Cell Focused Next-Generation SARS-CoV-2 Vaccine Candidate

Director recently bought kr26m worth of stock

Nykode Therapeutics Announces Phase 1/2 Clinical Trial With Next Generation DNA-Based COVID-19 Vaccine Candidates

Key Executive recently sold kr21m worth of stock

Vaccibody AS announced that it expects to receive NOK 178.305538 million in funding from Regeneron Pharmaceuticals, Inc.

Investor sentiment improved over the past week

Third quarter 2021 earnings released: US$0.03 loss per share (vs US$0.017 loss in 3Q 2020)

Director recently sold kr112m worth of stock

Second quarter 2021 earnings released: US$0.02 loss per share (vs US$0.02 loss in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: US$2.00 loss per share (vs US$0.011 loss in 1Q 2020)